Phase II study of homoharringtonine in patients with recurrent primary malignant central nervous system tumors

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

A phase 11 trial of Homoharringtonine (HHT) was performed in 15 patients with recurrent or progressive malignant glioma. The drug was administered at a initial dose of 4 mg/m 2/day by continuous 5 day intravenous infusion (3 mg/m 2/day x 5 days for heavily pretreated patients). Courses were repeated every 3-4 weeks upon recovery from toxicity. No objective antitumor regressions occurred. Two patients had no change in their CT brain scans for 2-3 months and one patient had stable disease for 6 months. Toxicity was tolerable and included myelosuppression and occasionally mild hypotension. Chemosensitivity testing with HHT and several other chemotherapy drugs was performed in glioma cell lines, including cell lines derived from these patients. The results suggest that HHT is an inactive drug in malignant glioma using this dose schedule.

Original languageEnglish
Pages (from-to)159-163
Number of pages5
JournalJournal of Neuro-Oncology
Volume9
Issue number2
DOIs
StatePublished - Oct 1 1990

Fingerprint

Central Nervous System Neoplasms
Glioma
Pharmaceutical Preparations
Cell Line
Intravenous Infusions
Hypotension
Appointments and Schedules
homoharringtonine
Drug Therapy
Brain

Keywords

  • central nervous system
  • homoharringtonine
  • tumor

ASJC Scopus subject areas

  • Neurology
  • Oncology
  • Clinical Neurology
  • Cancer Research
  • Neuroscience(all)

Cite this

@article{66bce385683d4b34a828d751fdb03ded,
title = "Phase II study of homoharringtonine in patients with recurrent primary malignant central nervous system tumors",
abstract = "A phase 11 trial of Homoharringtonine (HHT) was performed in 15 patients with recurrent or progressive malignant glioma. The drug was administered at a initial dose of 4 mg/m 2/day by continuous 5 day intravenous infusion (3 mg/m 2/day x 5 days for heavily pretreated patients). Courses were repeated every 3-4 weeks upon recovery from toxicity. No objective antitumor regressions occurred. Two patients had no change in their CT brain scans for 2-3 months and one patient had stable disease for 6 months. Toxicity was tolerable and included myelosuppression and occasionally mild hypotension. Chemosensitivity testing with HHT and several other chemotherapy drugs was performed in glioma cell lines, including cell lines derived from these patients. The results suggest that HHT is an inactive drug in malignant glioma using this dose schedule.",
keywords = "central nervous system, homoharringtonine, tumor",
author = "Feun, {Lynn G} and Niramol Savaraj and Howard Landy and Howard Levin and Theodore Lampidis",
year = "1990",
month = "10",
day = "1",
doi = "10.1007/BF02427837",
language = "English",
volume = "9",
pages = "159--163",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Phase II study of homoharringtonine in patients with recurrent primary malignant central nervous system tumors

AU - Feun, Lynn G

AU - Savaraj, Niramol

AU - Landy, Howard

AU - Levin, Howard

AU - Lampidis, Theodore

PY - 1990/10/1

Y1 - 1990/10/1

N2 - A phase 11 trial of Homoharringtonine (HHT) was performed in 15 patients with recurrent or progressive malignant glioma. The drug was administered at a initial dose of 4 mg/m 2/day by continuous 5 day intravenous infusion (3 mg/m 2/day x 5 days for heavily pretreated patients). Courses were repeated every 3-4 weeks upon recovery from toxicity. No objective antitumor regressions occurred. Two patients had no change in their CT brain scans for 2-3 months and one patient had stable disease for 6 months. Toxicity was tolerable and included myelosuppression and occasionally mild hypotension. Chemosensitivity testing with HHT and several other chemotherapy drugs was performed in glioma cell lines, including cell lines derived from these patients. The results suggest that HHT is an inactive drug in malignant glioma using this dose schedule.

AB - A phase 11 trial of Homoharringtonine (HHT) was performed in 15 patients with recurrent or progressive malignant glioma. The drug was administered at a initial dose of 4 mg/m 2/day by continuous 5 day intravenous infusion (3 mg/m 2/day x 5 days for heavily pretreated patients). Courses were repeated every 3-4 weeks upon recovery from toxicity. No objective antitumor regressions occurred. Two patients had no change in their CT brain scans for 2-3 months and one patient had stable disease for 6 months. Toxicity was tolerable and included myelosuppression and occasionally mild hypotension. Chemosensitivity testing with HHT and several other chemotherapy drugs was performed in glioma cell lines, including cell lines derived from these patients. The results suggest that HHT is an inactive drug in malignant glioma using this dose schedule.

KW - central nervous system

KW - homoharringtonine

KW - tumor

UR - http://www.scopus.com/inward/record.url?scp=0025071889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025071889&partnerID=8YFLogxK

U2 - 10.1007/BF02427837

DO - 10.1007/BF02427837

M3 - Article

VL - 9

SP - 159

EP - 163

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -